Global Skin Cancer Drugs Industry Outlook 2021: Overview, Opportunities, Key Companies and Forecast to 2027

Global Skin Cancer Drugs Industry Outlook 2021: Overview, Opportunities, Key Companies and Forecast to 2027

Report Code: KNJ1028747 | No. of Pages: 135 | Category: Pharmaceuticals and Healthcare
Publisher: GRD Survey | Date of Publish: Nov-2021
Executive Summary

According to GRD Survey data, the global Skin Cancer Drugs market was valued at  million US$ in 2020 and is expected to reach  million US$ by the end of 2027, growing at a CAGR of % in the forecast period between 2021 and 2027.

This report studies the Skin Cancer Drugs market dynamics from angles such as new entries, mergers and acquisitions, fundings, exit and major technology breakthroughs. Market performance is evaluated through market size (value and volume) by players, regions, product types and end industries. This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Skin Cancer Drugs in these regions, from 2016 to 2027, covering
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Italy, Spain and Russia, etc.)
    Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia)
    South America (Brazil, Argentina, Colombia, etc.)
    Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.)

Market Snapshot, By Product Type
    Actinic Keratoses

    Basal cell carcinoma

    Squamous cell carcinoma

    Melanoma

Market Snapshot, By Application
    Hospitals

    Laboratary

    Clinics

Main Market Players Analyzed in this report, including:
    Sun Pharmaceutical Industries Ltd.

    Pfizer

    PellePharm

    Novartis AG

    Meda

    Leo Pharma

    Eli Lilly

    Bristol Myers Squibb


The study objectives of this report are:
    To study and analyze the global Skin Cancer Drugs market size (value & volume) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027.
    To understand industry structure of Skin Cancer Drugs market by identifying its various subsegments.
    To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
    To identify the key global Skin Cancer Drugs manufacturers and regional typical players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
    To analyze the Skin Cancer Drugs market with respect to individual growth trends, future prospects, and their contribution to the total market.
    To project the value and volume of Skin Cancer Drugs submarkets, with respect to key regions (along with their respective key countries).
    To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
    To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Skin Cancer Drugs are as follows:
    History Year: 2016-2020
    Base Year: 2020
    Estimated Year: 2021
    Forecast Year 2021 to 2027

This report includes the estimation of market size in terms of value (million USD) and volume from top-down approach by analyzing major submarkets and their major driving factors, and verified from bottom-up approaches. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified from primary sources.

For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders Considered in the study:
Raw material vendors
Distributors/traders/wholesalers/suppliers
Regulatory authorities, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade/Industrial associations
End-use industries

Table of Contents

1  Market Definition & Scope
    1.1  Definition & Scope
    1.2 Skin Cancer Drugs Product Specifications
    1.3  Main Events (Entry, M&A, Exit, Technology and Capital Activity)
    1.4 Global Skin Cancer Drugs Market Performance and Outlook

2 Market Development Performance under COVID-19
    2.1 Influencing Factors of Industry Development in the Next Five Years
        2.1.1 Drivers
        2.1.2 Restraints
        2.1.3 Opportunities
    2.2 Porter’s Five Forces Analysis
    2.3 Comparison of Alternatives and Skin Cancer Drugs

3 Supply Chain and Manufacturing Cost Analysis
    3.1 Supply Chain Analysis
    3.2 Raw Materials and Key Suppliers Analysis
        3.2.1 Raw Materials Introduction
        3.2.1 Raw Materials Key Suppliers List
    3.3 Skin Cancer Drugs Sales Channel and Distributors Analysis
        3.3.1 Skin Cancer Drugs Sales Channel
        3.3.2 Skin Cancer Drugs Distributors
    3.4 Key Buying Industries/Consumers
        3.4.1 Major Buyers in Hospitals

        3.4.2 Major Buyers in Laboratary

    3.5 Skin Cancer Drugs Manufacturing Cost Structure Analysis

4 Market Segment: by Type
    4.1 Skin Cancer Drugs Type Introduction
        4.1.1 Actinic Keratoses

        4.1.2 Basal cell carcinoma

        4.1.3 Squamous cell carcinoma

        4.1.4 Melanoma
    4.2 Global Skin Cancer Drugs Sales by Type 2016-2021
    4.3 Global Skin Cancer Drugs Revenue by Type 2016-2021
    4.4 Global Skin Cancer Drugs Price by Type 2016-2021

5 Market Segment: by Application
    5.1 Skin Cancer Drugs Type Introduction
        5.1.1 Hospitals

        5.1.2 Laboratary

        5.1.3 Clinics
    5.2 Global Skin Cancer Drugs Sales by Application 2016-2021
    5.3 Global Skin Cancer Drugs Revenue by Application 2016-2021
    5.4 Global Skin Cancer Drugs Price by Application 2016-2021

6 Marke Segment: by Region
    6.1 Global Skin Cancer Drugs Market by Region
        6.1.1 Global Skin Cancer Drugs Sales by Regions
        6.1.2 Global Skin Cancer Drugs Revenue by Regions
    6.2 North America Skin Cancer Drugs Market 2016-2021
    6.3 Europe Skin Cancer Drugs Market 2016-2021
    6.4 Asia Pacific Skin Cancer Drugs Market 2016-2021
    6.5 South America Skin Cancer Drugs Market 2016-2021
    6.6 Middle East and Africa Skin Cancer Drugs Market 2016-2021

7 North America
    7.1 North America Skin Cancer Drugs Market by Country 2016-2021
        7.1.1 North America Skin Cancer Drugs Sales by Country
        7.1.2 North America Skin Cancer Drugs Revenue by Country
    7.2 United States
    7.3 Canada
    7.4 Mexico

8 Europe
    8.1 Europe Skin Cancer Drugs Market by Country 2016-2021
        8.1.1 Europe Skin Cancer Drugs Sales by Country
        8.1.2 Europe Skin Cancer Drugs Revenue by Country
    8.2 Germany
    8.3 France
    8.4 UK
    8.5 Italy
    8.6 Russia
    8.7 Spain

9 Asia Pacific
    9.1 Asia Pacific Skin Cancer Drugs Market by Country 2016-2021
        9.1.1 Asia Pacific Skin Cancer Drugs Sales by Country
        9.1.2 Asia Pacific Skin Cancer Drugs Revenue by Country
    9.2 China
    9.3 Japan
    9.4 Korea
    9.5 Southeast Asia
    9.6 India
    9.7 Australia

10 South America
    10.1 South America Skin Cancer Drugs Market by Country 2016-2021
        10.1.1 South America Skin Cancer Drugs Sales by Country
        10.1.2 South America Skin Cancer Drugs Revenue by Country
    10.2 Brazil
    10.3 Argentina
    10.4 Colombia

11 Middle East and Africa
    11.1 Middle East and Africa Skin Cancer Drugs Market by Country 2016-2021
        11.1.1 Middle East and Africa Skin Cancer Drugs Sales by Country
        11.1.2 Middle East and Africa Skin Cancer Drugs Revenue by Country
    11.2 Turkey
    11.3 Saudi Arabia
    11.4 South Africa

12 Key Participants Company Information
    12.1 Sun Pharmaceutical Industries Ltd.

        12.1.1 Sun Pharmaceutical Industries Ltd.
 Company Information
        12.1.2 Sun Pharmaceutical Industries Ltd.
 Skin Cancer Drugs Product Portfolio, Specification and Application
        12.1.3 Sun Pharmaceutical Industries Ltd.
 Skin Cancer Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
        12.1.4 Sun Pharmaceutical Industries Ltd.
 Key Development
    12.2 Pfizer

        12.2.1 Pfizer
 Company Information
        12.2.2 Pfizer
 Skin Cancer Drugs Product Portfolio, Specification and Application
        12.2.3 Pfizer
 Skin Cancer Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
        12.2.4 Pfizer
 Key Development
    12.3 PellePharm

        12.3.1 PellePharm
 Company Information
        12.3.2 PellePharm
 Skin Cancer Drugs Product Portfolio, Specification and Application
        12.3.3 PellePharm
 Skin Cancer Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
        12.3.4 PellePharm
 Key Development
    12.4 Novartis AG

        12.4.1 Novartis AG
 Company Information
        12.4.2 Novartis AG
 Skin Cancer Drugs Product Portfolio, Specification and Application
        12.4.3 Novartis AG
 Skin Cancer Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
        12.4.4 Novartis AG
 Key Development
    12.5 Meda

        12.5.1 Meda
 Company Information
        12.5.2 Meda
 Skin Cancer Drugs Product Portfolio, Specification and Application
        12.5.3 Meda
 Skin Cancer Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
        12.5.4 Meda
 Key Development
    12.6 Leo Pharma

        12.6.1 Leo Pharma
 Company Information
        12.6.2 Leo Pharma
 Skin Cancer Drugs Product Portfolio, Specification and Application
        12.6.3 Leo Pharma
 Skin Cancer Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
        12.6.4 Leo Pharma
 Key Development
    12.7 Eli Lilly

        12.7.1 Eli Lilly
 Company Information
        12.7.2 Eli Lilly
 Skin Cancer Drugs Product Portfolio, Specification and Application
        12.7.3 Eli Lilly
 Skin Cancer Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
        12.7.4 Leo Pharma
 Key Development
        12.8.1 Bristol Myers Squibb
 Company Information
        12.8.2 Bristol Myers Squibb
 Skin Cancer Drugs Product Portfolio, Specification and Application
        12.8.3 Bristol Myers Squibb
 Skin Cancer Drugs Sales, Price, Revenue and Gross Margin (2019-2021)
        12.8.4 Bristol Myers Squibb
 Key Development

13 Global Skin Cancer Drugs Market Forecast by Region by Type and by Application
    13.1 Global Skin Cancer Drugs Sales, Revenue Forecast 2022-2027
    13.2 Global Skin Cancer Drugs Forecast by Regions
        13.2.1 Global Skin Cancer Drugs Sales Forecast by Region 2022-2027
        13.2.2 Global Skin Cancer Drugs Revenue Forecast by Region 2022-2027
    13.3 Global Skin Cancer Drugs Forecast by Type
        13.3.1 Global Skin Cancer Drugs Sales Forecast by Type 2022-2027
        13.3.2 Global Skin Cancer Drugs Revenue Forecast by Type 2022-2027
        13.3.3 Global Skin Cancer Drugs Price Forecast by Type 2022-2027
    13.4 Global Skin Cancer Drugs Forecast by Application
        13.4.1 Global Skin Cancer Drugs Sales Forecast by Application 2022-2027
        13.4.2 Global Skin Cancer Drugs Revenue Forecast by Application 2022-2027
        13.4.3 Global Skin Cancer Drugs Price Forecast by Application 2022-2027

14 Analyst Views and Conclusions

15 Methodology and Data Source
    15.1 Methodology
    15.2 Research Data Source
        15.2.1 Secondary Data
        15.2.2 Primary Data
        15.2.3 Market Size Estimation
    15.3 Legal Disclaimer

NEED Help?

If you need any help or guidance, please feel free to call us.

USA : +1 (661) 636 6162

INDIA : +91 9325802062

or

Write us on : sales@kandjmarketresearch.com